- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07520461
Microbiome-targeted Diet Therapy in Ulcerative Colitis
May 18, 2026 updated by: University of Minnesota
The central objective of this proposal is to test a novel diet capable of meeting the elevated protein requirements in ulcerative colitis (UC), while simultaneously decreasing microbial hydrogen sulfide (H2S) production in the colon with fiber.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lulu Chen
- Phone Number: 612-301-8294
- Email: chen8124@umn.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ability and willingness to provide informed consent
- Age at least 18 years old
- Diagnosis of UC based on clinical and endoscopic criteria
- UC duration of at least 3 months
- Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score ≤4 within 90 days of randomization
On a stable dose or no existing UC therapies (apart from steroids) for defined periods (as outlined below).
- ≥4 weeks if no medication, 5-ASA
- ≥8 wk for immunomodulatory therapy
- ≥12 wk for biologics
- Ability to comply with study requirements in the opinion of the primary investigator
Exclusion Criteria:
- Moderate or severe UC as defined by UCEIS ≥5
- History of stomach surgery or bowel resection
- Antibiotic use within 3 months
- Anticipated antibiotic exposure during the study period (e.g. perioperative antibiotics)
- Pregnancy or breastfeeding
- History of anaphylactic food allergies
- Intolerance of high dietary fiber content
- Ongoing alcohol or drug abuse
- Habitual vegan diet pattern
- Insufficient freezer space to accommodate meal delivery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: On-Off Cycling Intervention
1 week standard diet, followed by 1 week high-protein, high-fiber diet, followed by 1 week standard diet, followed by 1 week high-protein, high-fiber diet |
The HPHF diet is a diet designed to maximize the intake of proteins and fermentable dietary fibers.
Frozen meals are provided to participants weekly and consumed over two non-consecutive 7-day periods.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fecal H2S Production
Time Frame: Week 4
|
Assessed from stool samples
|
Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Levi Teigen, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 6, 2026
Primary Completion (Estimated)
June 1, 2029
Study Completion (Estimated)
June 1, 2029
Study Registration Dates
First Submitted
April 2, 2026
First Submitted That Met QC Criteria
April 2, 2026
First Posted (Actual)
April 9, 2026
Study Record Updates
Last Update Posted (Actual)
May 19, 2026
Last Update Submitted That Met QC Criteria
May 18, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GI-2026-34620
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Eli Lilly and CompanyRecruitingUlcerative Colitis, Active Severe | Ulcerative Colitis (UC) | Ulcerative Colitis, Active ModerateUnited States, China, Croatia, France, India, Japan, Israel, Taiwan, Brazil, Serbia, Greece, Hungary, Argentina, Italy, Poland, Czechia, Colombia, Lithuania, Latvia, Ukraine, South Africa, Portugal, Mexico, Canada, Slovakia, Turkey (Türkiye) and more
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtCompletedUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Alexion Pharmaceuticals, Inc.Immune PharmaceuticalsTerminatedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
-
Odyssey TherapeuticsRecruitingUlcerative Colitis (UC) | UC - Ulcerative ColitisAustralia, Austria, Jordan, Poland, Ukraine, New Zealand, Canada, Czechia, Lithuania, Moldova
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MRSU 938 - Research Center of Saint...Not yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Tanta UniversityRecruitingUlcerative Colitis | Ulcerative Colitis (UC)Egypt
-
NIBEC Co., Ltd.CompletedHealthy Adult Volunteers | Active Ulcerative Colitis | Active Ulcerative Colitis (UC)Australia
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
Clinical Trials on High Protein, High Fiber (HPHF) Diet
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedPrimary Biliary CirrhosisMexico
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedCirrhosis | Autoimmune HepatitisMexico
-
University of VirginiaCompletedObesity | Food Preferences | Hunger | Ingestive BehaviorUnited States
-
Örebro University, SwedenUniversity of Helsinki; European Innovation CouncilRecruitingHealthy Adults | Dietary Fiber FermentationSweden
-
Mayo ClinicCompleted
-
Purdue UniversityCompletedObesity | Dietary Modification | Lack of Satiety | Memory DeficitsUnited States
-
King Faisal UniversitySaudi Food and Drug AuthorityRecruitingDietary Intervention | Glycemic Response; Satiety | Postprandial Glucose | Fasting, Time RestrictedSaudi Arabia
-
University of TorontoCanadian Institutes of Health Research (CIHR)CompletedObesity | Cardiovascular Disease | Type 2 Diabetes MellitusCanada
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed